Literature DB >> 9539350

Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.

N Syed1, J Murphy, T Zimmerman, M H Mark, J I Sage.   

Abstract

We report our long-term experience using enteral levodopa infusions in 22 patients with Parkinson's disease and severe motor fluctuations. Amelioration of intractable dyskinesias was the most important factor that determined whether patients chose to continue using the infusion pump system. Mechanical and physical problems associated with enteral access were the most common reasons for which patients discontinued pump use. Nearly all patients continued to have dramatically increased on time for the duration of follow up, suggesting that technically less-cumbersome systems that provide continuous dopaminergic stimulation are worthwhile and should be developed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9539350     DOI: 10.1002/mds.870130222

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

1.  Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

Authors:  O K Sujith; Carol Lane
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 2.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

3.  Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.

Authors:  Giovanni Cossu; Valeria Ricchi; Manuela Pilleri; Francesca Mancini; Daniela Murgia; Gianluigi Ricchieri; Alessandra Mereu; Maurizio Melis; Angelo Antonini
Journal:  Neurol Sci       Date:  2015-05-05       Impact factor: 3.307

Review 4.  Transdermal treatment options for neurological disorders: impact on the elderly.

Authors:  Lorenzo Priano; Maria Rosa Gasco; Alessandro Mauro
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  Pain in Parkinson's Disease.

Authors:  Jacob I. Sage
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

Review 6.  Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Authors:  Werner Poewe; Angelo Antonini; Jan Cm Zijlmans; Pierre R Burkhard; François Vingerhoets
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

7.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

9.  Potential cellular and regenerative approaches for the treatment of Parkinson's disease.

Authors:  Emma L Lane; Olivia J Handley; Anne E Rosser; Stephen B Dunnett
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

Review 10.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.